Adherence To Current Guidelines For Chronic Obstructive Pulmonary Disease (COPD) In Subjects Treated With Combination Of Long-Acting Beta2-Agonist (LABA), Long-Acting Muscarinic Antagonist (LAMA) Or Inhaled Corticosteroids (ics)

被引：0
|
作者：
Asche, C. V.
Leader, S.
Plauschinat, C.
Raparla, S.
Yan, M.
Ye, X.
Young, D.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2011年 / 183卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3115
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ADHERENCE TO CURRENT GUIDELINES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SUBJECTS TREATED WITH COMBINATION OF LONG-ACTING B2-AGONIST (LABA), LONG-ACTING MUSCARINIC ANTAGONIST (LAMA) OR INHALED CORTICOSTEROIDS (ICS)
    Asche, C.
    Leader, S.
    Plauschinat, C.
    Raparla, S.
    Ye, X.
    Yan, M.
    Young, D.
    VALUE IN HEALTH, 2011, 14 (07) : A492 - A492
  • [2] Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
    Horita, Nobuyuki
    Goto, Atsushi
    Shibata, Yuji
    Ota, Erika
    Nakashima, Kentaro
    Nagai, Kenjiro
    Kaneko, Takeshi
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (02):
  • [3] Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
    Fukuda, Nobuhiko
    Horita, Nobuyuki
    Kaneko, Ayami
    Goto, Atsushi
    Kaneko, Takeshi
    Ota, Erika
    Kew, Kayleigh M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (06):
  • [4] Comparative Effectiveness of Long-Acting Beta2-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease
    Samp, Jennifer C.
    Joo, Min J.
    Schumock, Glen T.
    Calip, Gregory S.
    Pickard, A. Simon
    Lee, Todd A.
    PHARMACOTHERAPY, 2017, 37 (04): : 447 - 455
  • [5] COMPARISON OF MONOTHERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST VERSUS COMBINATION THERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST PLUS A LONG-ACTING BETA2-AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Yosuke, Tanaka
    Mitsunori, Hino
    Naomi, Onda
    Hiroyuki, Takoi
    Seiji, Kosaihira
    Norihisa, Motohashi
    Akihiko, Gemma
    RESPIROLOGY, 2014, 19 : 122 - 122
  • [6] Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
    Kew, Kayleigh M.
    Dahri, Karen
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (01):
  • [7] Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease
    van Geffen, Wouter H.
    Tan, Daniel J.
    Walters, Julia A. E.
    Walters, E. Haydn
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (12):
  • [8] Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease
    Tan, Daniel J.
    White, Clinton J.
    Walters, Julia A. E.
    Walters, E. Haydn
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (11):
  • [9] Characterization Of COPD Patients Treated With Inhaled Triple Therapy Containing Inhaled Corticosteroids [ics], Long-Acting Beta2-Agonists [laba], And Long-Acting Muscarinic Antagonists [lama] In The Uk
    Mullerova, H.
    Maskell, J.
    Meeraus, W. H.
    Galkin, D.
    Albers, F. C.
    Gait, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [10] Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
    Asche, Carl Victor
    Leader, Shelah
    Plauschinat, Craig
    Raparla, Swetha
    Yan, Ming
    Ye, Xiangyang
    Young, Dave
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 : 201 - 209
12345